Background
Cristina Adriana Popa
A dose of CONFIDENCE: Building evidence for ...

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Background
swapnil hiremath
From single shots to strategy: How CAPTIVATE is ...

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Background
Cristina Adriana Popa
Are E-Nudges Enough to Push Guideline-Based CKD ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

Are E-Nudges Enough to Push Guideline-Based CKD Therapy?
Background
Brian Rifkin
STAMP of Approval: Tacrolimus vs MMF in ...

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance

michelle fravel

Resumen Visual Ensayo CONFIDENCE

El ensayo CONFIDENCE evaluó la combinación de finerenona + empagliflozina en ERC + DM2: mayor reducción de CACu a 180 días. ¿Estamos listos para iniciar la terapia combinada desde el principio?

Revisa el resumen visual por Michelle Fravel